GlassScriptPhysician profile
Joseph Mario Pyles
NPI 1255330981
$12,697.83
in general payments reported to CMS, 2019-2025
32 companies · $906 in 2025
The $906 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,983 · 2020: $2,597 · 2021: $562 · 2022: $3,017 · 2023: $1,509 · 2024: $1,124 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,538.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $4,228.79 | 2019-2020 | |
| Boston Scientific Corporation | $2,733.87 | 2019-2024 | Watchman Access System, Avvigo Guidance System, Watchman Flx |
| Abbott Laboratories | $1,035.62 | 2019-2025 | Diamondback Coronary, Confirm Rx, Dragonfly Opstar |
| E.R. Squibb & Sons, L.L.C. | $656.09 | 2019-2025 | Eliquis, Camzyos |
| Shockwave Medical, INC | $592.22 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $501.02 | 2021-2025 | Jardiance |
| Biotronik INC. | $342.25 | 2023-2024 | Orsiro Mission, Pk Papyrus, Nhancer Rx |
| Novartis Pharmaceuticals Corporation | $328.24 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $290.06 | 2019-2024 | Brilinta, Wainua |
| Janssen Pharmaceuticals, INC | $264.89 | 2019-2023 | Xarelto |
| Stryker Corporation | $204.43 | 2025 | Clottriever Bold Catheter |
| Amgen INC. | $197.88 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $166.81 | 2019-2023 | |
| Teleflex LLC | $165.45 | 2023 | Guideliner |
| Medtronic, INC. | $143.35 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $121.27 | 2025 | |
| Edwards Lifesciences Corporation | $115.56 | 2022-2025 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $96.92 | 2024-2025 | Ozempic |
| Amarin Pharma, INC. | $91.58 | 2019 | |
| Pfizer INC. | $88.44 | 2019-2023 | |
| Chiesi USA, INC. | $87.60 | 2020-2021 | |
| Kestra Medical Technology Services, INC. | $46.32 | 2024 | Assure Wcd |
| Inari Medical, INC. | $44.50 | 2022 | |
| Terumo Medical Corporation | $25.85 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.61 | 2022 | |
| Vifor Pharma, INC. | $19.95 | 2020 | |
| Cardiovascular Systems INC. | $18.50 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.97 | 2019 | |
| Daiichi Sankyo INC. | $14.69 | 2019 | |
| Merck Sharp & Dohme LLC | $13.40 | 2021 | |
| Gilead Sciences, INC. | $13.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Pyles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.